Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 feasibility study of bertilimumab in moderate to severe bullous pemphigoid
MOH_2017-05-11_000400Phase 2Recruiting
- Sponsor
- Immune Pharmaceuticals Inc.
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bertilimumab in Bullous Pemphigoid (BP), sponsored by Immune Pharmaceuticals Inc. Started Nov 2015; status: recruiting.
02
Drugs
bertilimumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on MOH_2017-05-11_000400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-11_000400.